Advanced search
Start date
Betweenand

Development of a Low Cost Insulin Infusion Pump

Grant number: 18/22094-0
Support type:Research Grants - Innovative Research in Small Business - PIPE
Duration: December 01, 2020 - November 30, 2022
Field of knowledge:Engineering - Electrical Engineering - Industrial Electronics, Electronic Systems and Controls
Principal researcher:Sebastião Vagner Arêdes
Grantee:Sebastião Vagner Arêdes
Company:Aredes Equipamentos Hospitalares Ltda
CNAE: Atividades de serviços de complementação diagnóstica e terapêutica
City: São José dos Campos
Principal researchers:Luiz Eduardo Galvão Martins ; Tatiana de Sousa da Cunha Uchiyama
Assoc. researchers:Dulce Elena Casarini ; Jane Dullius ; Juliana Almada Colucci Barros ; Monica Andrade Lima Gabbay ; Sergio Atala Dib ; Tiago de Oliveira

Abstract

The worldwide prevalence of diabetes melito (DM) has exponentially increased in the last decades. According to the World Health Organization this phenomenon acquired epidemic characteristics in several countries. If DM is not properly treated it can lead to very high social and economic costs. DM is the third major cause of premature mortality and it represents one of the most costs to the public health systems. The current estimation is that more than 425 million people suffer with DM, with about 75% of the cases in development countries. In Brazil, data from the Vigilance of Risk Factors and Protection against Chronical Diseases by Phone Inquire (Vigitel) showed that the prevalence of DM in the population above 18 years increased from 5.5% to 8.9% (between 2006 and 2016). Brazil is the fourth country in the world with DM, reaching about 16 million people. About 20-25% of people with DM need treatment with several daily application of injectable insulin, especially children and adolescents. At the end of the 20th Century several advances have happened in the diabetes treatment, which improved the management of the disease and their complications. Among the advances, we can pointed out the development of the insulin infusion pump, which is used in USA since 1970, but in Brazil only in the last 15 years it has been prescribed with more frequency. Approximately 15% of DM1 carriers have absolute indication to use insulin infusion pump, and despite the benefits of such a treatment the numbers of patients that can afford it is still much reduced, especially in Brazil. The main limitation to use this treatment is the high cost of the equipment, since the insulin infusion pumps available in Brazilian market are imported and their cost are about R$ 15.000,00. Therefore, this cost is prohibitive for the most part of the people with indication of using it. The aim of this project is to develop and produce an insulin infusion pump of low-cost, which will benefit the population that need such medical device, but can't afford its acquisition. The development of this project will place Brazil among the countries with technological skills to produce an insulin infusion pump of low-cost, aiming to supply the Brazilian market, with possibilities to expand for Latin-American, African and Asian markets. (AU)

Articles published in Agência FAPESP Newsletter about the research grant: